Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection

被引:152
作者
Rhee, EG
Mendez, S
Shah, JA
Wu, CY
Kirman, JR
Turon, TN
Davey, DF
Davis, H
Klinman, DM
Coler, RN
Sacks, DL
Seder, RA
机构
[1] NIAID, Cellular Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA
[2] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA
[3] Coley Pharmaceut Grp, Ottawa, ON K1Y 4S1, Canada
[4] US FDA, Ctr Biol Evaluat & Res, Lab Retrovirol & Immunol, Bethesda, MD 20892 USA
[5] Infect Dis Res Inst, Seattle, WA 98104 USA
关键词
CD4(+) T cells; CD8(+) T cells; DNA vaccines; parasitic infection; Th cells;
D O I
10.1084/jem.20020147
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CpG oligodeoxynucleotides (ODN) have potent effects on innate and adaptive cellular immune responses,. In this report, the ability, of CpG ODN to confer long-term immunity and protection when used as a vaccine adjuvant with a clinical grade of leishmanial antigen, autoclaved Leishmania major (ALM), or a recombinant leishmanial protein was studied. In two different Mouse models of L. major infection, vaccination with ALM plus CpG ODN was able to control infection and markedly reduce lesion development in susceptible BALB/c and resistant C57BL/6 (B6) mice, respectively, up to 12 wk after immunization. Moreover, 136 mice immunized with ALM plus CpG ODNs were still protected against infectious challenge even 6 mo after vaccination. In terms of immune correlates of protection, ALM plus CpG ODN-vaccinated mice displayed L. major-specific T helper cell I and CD8(+) response,;. In addition. complete protection was markedly abrogated in mice depleted of CD8(+) T cells at the time of vaccination. Similarly, mice vaccinated with a recombinant leishmanial protein plus CpG ODN also had long-term protection that was dependent on CD8(+) T cells in vivo. Together, these data demonstrate that CpG ODN, when used as a vaccine adjuvant with either a recombinant protein or heat-killed leishmanial antigen, can induce long-term protection against an intracellular infection in a CDS-dependent manner.
引用
收藏
页码:1565 / 1573
页数:9
相关论文
共 37 条
  • [1] THE ADJUVANT EFFECT OF INTERLEUKIN-12 IN A VACCINE AGAINST LEISHMANIA-MAJOR
    AFONSO, LCC
    SCHARTON, TM
    VIEIRA, LQ
    WYSOCKA, M
    TRINCHIERI, G
    SCOTT, P
    [J]. SCIENCE, 1994, 263 (5144) : 235 - 237
  • [2] Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs
    Ballas, ZK
    Krieg, AM
    Warren, T
    Rasmussen, W
    Davis, HL
    Waldschmidt, M
    Weiner, GJ
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (09) : 4878 - 4886
  • [3] A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity
    Belkaid, Y
    Mendez, S
    Lira, R
    Kadambi, N
    Milon, G
    Sacks, D
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (02) : 969 - 977
  • [4] CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major
    Belkaid, Y
    Von Stebut, E
    Mendez, S
    Lira, R
    Caler, E
    Bertholet, S
    Udey, MC
    Sacks, D
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (08) : 3992 - 4000
  • [5] Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease
    Campos-Neto, A
    Porrozzi, R
    Greeson, K
    Coler, RN
    Webb, JR
    Seiky, YAW
    Reed, SG
    Grimaldi, G
    [J]. INFECTION AND IMMUNITY, 2001, 69 (06) : 4103 - 4108
  • [6] Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism
    Cho, HJ
    Takabayashi, K
    Cheng, PM
    Nguyen, MD
    Corr, M
    Tuck, S
    Raz, E
    [J]. NATURE BIOTECHNOLOGY, 2000, 18 (05) : 509 - 514
  • [7] CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
    Chu, RS
    Targoni, OS
    Krieg, AM
    Lehmann, PV
    Harding, CV
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) : 1623 - 1631
  • [8] COLER RN, 2002, IN PRESS INFECT IMMU
  • [9] Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity
    Davila, E
    Celis, E
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (01) : 539 - 547
  • [10] Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination:: A potential immunoregulatory role for CD8+ T cells
    Gurunathan, S
    Stobie, L
    Prussin, C
    Sacks, DL
    Glaichenhaus, N
    Fowell, DJ
    Locksley, RM
    Chang, JT
    Wu, CY
    Seder, RA
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (02) : 915 - 924